EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists. The 2025 European Society of Retina ...
The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies. The US Food and Drug Administration (FDA) has granted Priority Review to Chiesi Global ...
Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD. Luxa is a clinical-stage biotechnology ...
Conavi Medical has submitted its Novasight Hybrid IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. Conavi’s ...
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
The European Commission (EC) has granted marketing authorization for EYLUXVI (ALT-L9), an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics. 1 EYLUXVI is ...
Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment. Kalaris Therapeutics announced the company ...
Justis P. Ehlers, MD, FASRS, presented at the Retina Society meeting in Chicago, Illinois. His talk focused on the data from the HELIOS phase 1 trial, exploring a novel treatment for nonproliferative ...
Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space. Modern imaging technologies, like advanced forms of optical coherence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback